

Ardelyx Announces Presentation at J.P. Morgan 36th Annual Healthcare Conference

January 3, 2018



To access the live webcast of Ardelyx's presentation please visit the Events & Presentations page within the livestor page of the Ardelyx website at Landelyx corp. Replays of the webcast will be available on the Ardelyx website for 60 days following the conference.

About Ardetyx, Inc. Ardety is located on enhancing the way people with cardiorenal diseases are treated by developing differentiated, minimally systemic medicines. Ardety's: cardiorenal pipeline includes the Phase 3 development of the treatment of propriors harden to the treatment of hyperphosphatemia in people with and stage renal disease who are on dalysis and RDX013, a potassium secretagogue program for the proprint areament of hyperphosphatemia in people with and stage renal disease who are on dalysis and RDX013, a potassium secretagogue program for the proprint areament of hyperphosphatemia in proprint and area of the treatment of people with intrabates bowly syndrome with constpation and articipates aubmitting a New Dug Application to the U.S. Food and Dug Administration for this indication in the second half of 2018. To efficiently bring is treatments to market, Ardety is puring strategic collaborations in the U.S. and beyond, with established agreements with Foosin Pharma in China and Kyowa Hakko Kirin in Japan. For more information, please visit <u>from Xinon and articipates</u> and chine differentiates.

C View original con

SOURCE Ardelyx Monique Allaire, THRUST IR, 781-631-0759, monique@thrustir.com or Alicia Davis, THRUST IR, 910-620-3302, alicia@thrustir.com